NCT06550011View on ClinicalTrials.gov

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2030

Conditions
Neovascular (Wet) AMD
Interventions
DRUG

ABI-110 Low Dose

Low dose. lower than the safety factor of 10 as recommended by the FDA

DRUG

ABI-110 Medium Dose

Medium dose

DRUG

ABI-110 High Dose

High Dose

Trial Locations (4)

77384

RECRUITING

Retina Consultants of Texas, The Woodlands

78240

RECRUITING

Retina Consultants of Texas - San Antonio, San Antonio

93309

RECRUITING

California Retina Consultants, Bakersfield

94598

RECRUITING

Bay Area Retina Associates, Walnut Creek

Sponsors
All Listed Sponsors
lead

Avirmax Biopharma Inc

INDUSTRY